A Phase 1, Randomized, Crossover, Open-label, 4 Period Study In Healthy Volunteers To Demonstrate The Lack Of Effect Of Rabeprazole And Food On The Pharmacokinetics Of PF-06463922 And To Assess The Relative Bioavailability Of Oral Solution To The Tablet Formulation Of PF-06463922
Phase of Trial: Phase I
Latest Information Update: 24 Mar 2018
At a glance
- Drugs Lorlatinib (Primary) ; Lorlatinib (Primary) ; Rabeprazole
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Pfizer
- 24 Mar 2018 Results presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 11 May 2016 Status changed from recruiting to completed.
- 04 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Apr 2016, according to ClinicalTrials.gov record.